Parsons Capital Management Inc. RI Decreases Stock Holdings in Danaher Corporation $DHR

Key Points

• Parsons Capital Management Inc. RI reduced its holdings in Danaher Corporation by 38.9%, selling 17,463 shares and now owning a total of 27,450 shares valued at approximately $5.42 million.
• Danaher reported strong fiscal performance, with earnings per share of $1.80 for the last quarter, exceeding analysts' expectations of $1.64, and a revenue of $5.94 billion, reflecting a 3.4% year-over-year increase.
• The company announced a quarterly dividend of $0.32 per share, marking a 0.6% dividend yield, with the ex-dividend date set for September 26.

Parsons Capital Management Inc. RI reduced its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 38.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 27,450 shares of the conglomerate's stock after selling 17,463 shares during the period. Parsons Capital Management Inc. RI's holdings in Danaher were worth $5,423,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. RKL Wealth Management LLC lifted its position in shares of Danaher by 2.7% during the 2nd quarter. RKL Wealth Management LLC now owns 4,178 shares of the conglomerate's stock worth $825,000 after purchasing an additional 111 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its position in shares of Danaher by 161.2% during the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 175,724 shares of the conglomerate's stock worth $34,713,000 after purchasing an additional 108,448 shares during the last quarter. Woodward Diversified Capital LLC purchased a new stake in shares of Danaher during the 2nd quarter worth $348,000. Community Financial Services Group LLC lifted its position in shares of Danaher by 5.2% during the 2nd quarter. Community Financial Services Group LLC now owns 19,371 shares of the conglomerate's stock worth $3,827,000 after purchasing an additional 960 shares during the last quarter. Finally, Childress Capital Advisors LLC lifted its position in shares of Danaher by 10.6% during the 2nd quarter. Childress Capital Advisors LLC now owns 1,797 shares of the conglomerate's stock worth $355,000 after purchasing an additional 172 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of the company's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 11.10% of the company's stock.

Danaher Price Performance

Shares of NYSE:DHR opened at $212.92 on Thursday. The company has a 50-day simple moving average of $199.85 and a 200-day simple moving average of $197.42. Danaher Corporation has a one year low of $171.00 and a one year high of $279.41. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The stock has a market capitalization of $152.46 billion, a price-to-earnings ratio of 45.30, a PEG ratio of 2.82 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. During the same period in the prior year, the company earned $1.72 earnings per share. The business's revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher's dividend payout ratio is presently 27.23%.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on DHR shares. Wall Street Zen raised shares of Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Robert W. Baird boosted their price target on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research report on Friday, July 18th. Scotiabank raised shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target for the company in a research report on Friday, July 11th. Royal Bank Of Canada set a $241.00 price target on shares of Danaher in a research report on Tuesday, September 2nd. Finally, Wells Fargo & Company reduced their price target on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a research report on Wednesday, July 23rd. Seventeen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $245.91.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.